Anti-Cancer Agents in Medicinal Chemistry · 2018 · 18 citations · 29 references
MedicineCancer BiologyOncologyCarcinogenesisGene ExpressionMolecular OncologyCancer BiomarkersGastric CancerMicrorna BiologyMicrorna-mediated RegulationMolecular Tumor ProfilingNoncoding Rna In CancerAssayBiomarkers Of Gastric CancerMicrorna BiomarkersMicrorna Function In CancerMicrorna In CancerMicrorna Regulation In CancerReal-time Polymerase Chain Reaction (Pcr)Reverse Transcription Polymerase Chain Reaction (Rt-pcr)
BACKGROUND: MicroRNAs are noncoding RNAs which play critical roles in response to anti-cancer agents. Let-7a and miR-21 are well-known tumor-suppressor and oncomiR miRNAs, respectively. They are involved in tumorigenesis of gastric cancer and have potential to be used as markers in response to the therapy. OBJECTIVE: We aimed to study alterations in the expression of Let-7a and miR-21, and their targets in gastric cancer cell lines after treatment with docetaxel. METHODS: In order to determine the IC50 of docetaxel, MTT assay was performed in AGS, MKN45 and KATO III gastric cancer cell lines. The expression levels of Let-7a and miR-21 and their target genes, HMGA2 and PDCD4, were determined by reverse-transcription quantitative real-time PCR for both treated and untreated cell lines. RESULTS: MTT assay showed higher IC50 concentration of docetaxel in KATO III in comparison with AGS and MKN45, indicating KATO III`s higher resistance to docetaxel. Following the treatment, the expression level of Let-7a was significantly increased in AGS and MKN45, while decreased in KATO III. Expression level of miR- 21 in the three treated cell lines was increased significantly. Not only Let-7a, but also expression level of HMGA2 and PDCD4 genes showed different patterns in KATO III in comparison with AGS and MKN45. CONCLUSION: Down-regulation and up-regulation of Let-7a in docetaxel-resistant and sensitive cell lines, respectively indicates its potential usefulness as biomarker for responsiveness of gastric cancer to the therapy with docetaxel and also for predicting patient`s outcome.
29
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine · 2007 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +11
Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai et al. · Journal of Clinical Oncology · 2011 · 1.5K citations · Full text
miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells
Lin Xia, Dexin Zhang, Rui Du et al. · International Journal of Cancer · 2008 · 718 citations · Full text
Medicine, Oncology, Pharmacology +17
Emerging role of microRNA-21 in cancer
Yin‐Hsun Feng, Chao‐Jung Tsao · Biomedical Reports · 2016 · 454 citations · Full text
Medicine, Cancer Biology, Oncology +17